Find a Health Care Professional / Researcher

Jamie L. Wooldridge, MD

Appointment

Assistant Professor, Department of Pediatrics, Division of Pulmonary Medicine

Email

jamie.wooldridge@cchmc.org

Phone

513-636-6771

Fax

513-636-4615

Credentials

MD: Indiana University, Indianapolis, IN 1995.
Residency: Pediatrics, Indiana University, Indianapolis, IN, 1998.
Fellowship: Pediatric Pulmonology, University of Colorado Health Sciences Center, 2001.
Ceritification: Pediatrics, 1998; Pediatric Pulmonology, 2002.

Research

Cystic Fibrosis related diabetes

Research Grants and Contracts

Cystic Fibrosis Foundation- Research Development Project Grant ( Program P.I. Christopher Karp)- “Development of inflammation and catabolism in infacnt with CF (Project P.I.- Jamie Wooldridge) - 9/1/08-8/31/10- submitted 1/15/08

CCHMC Trustee application (P.I. Jamie Wooldridge) - “Low dose, long acting insulin to improve the catabolism of non-diabetic cystic fibrosis (CF) Patients: A pilot study” – 7/1/08 – 6/30/09

Clinical Research Feasibility Funds (CReFF) award/CCHMC (P.I. Jamie Wooldridge) - “Low dose, long acting insulin to improve the catabolism of non-diabetic cystic fibrosis (CF) Patients: A pilot study” – 7/1/07-6/29/07

Translational Research Initiative /Cincinnati Children’s Research Foundation/CCHMC (P.I. Bruce Trapnell)—Serum Surfactant Protein-D as a Biomarker of Cystic Fibrosis Lung Disease—Role: Clinical Principal Investigator—20% of total effort, 7/1/06-6/30/07

National Institute of Child Health and Human Development, Child Health Research Career Development Award “Expression and localization of S100A8 and S100A9 in the presence and absence of CFTR” 2 K12 HD28827-11, 75% Effort, Scholar position, 7/1/02–6/30/04, Peer-reviewed

Cystic Fibrosis Foundation grant (3/1/01-2/28/04) “Effects of P. aeruginosa on Inflammatory Gene Expression: Project 1-Airway Epithelial Cell Genomics and Pseudomonas Aeruginosa Infections in Patients with Cystic Fibrosis” Rodman00V0, Role- Co-Investigator

Cystic Fibrosis Foundation 4th year Clinical Fellowship Grant (2001-2002)

“The Nitric Oxide Pathway in the Airways of Infants and Children with Cystic Fibrosis” Wooldr01A0

Cystic Fibrosis Foundation 3rd year Clinical Fellowship Grant (2000-2001)“Nitric Oxide in Early Cystic Fibrosis” Wooldr00D0

Cystic Fibrosis Foundation 2nd year Clinical Fellowship Grant (1999-2000) Wooldr99B0

Cystic Fibrosis Foundation 1st year Clinical Fellowship Grant (1998-1999) Wooldr98B0

Gilead Sciences, Inc.-A Double-Blinded, Multicenter, Multinational, Randomized, Placebo Controlled Trial Evaluating Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis, Mild Lung Disease, and P. aeruginosa #AIR-CF4. Active

Bayer Pharmaceuticals, Inc.-Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosis #12429. Active

Inspire Pharmaceuticals, Inc – A Multi-Centered, Double-Blind, Placebo-Controlled Randomized, Efficacy and Safety Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Mild Cystic Fibrosis Lung Disease. #08-108. Active

Boehringer Ingelheim Pharmaceuticals, Inc – A Randomized, Double-Blind within Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability , and Pharmacokinetics of Increasing Single and Multiple Doses (28-day dosing) to Tiotropium Bromide Administered Once Daily via Respimat Device in Cystic Fibrosis Patients. #205-338. Active

Eurand, S.p.A. - An Open-Label Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) Microtabs" in Pediatric Patients with Cystic Fibrosis and Exocrine Pancreatic Insufficiency. EUR-1009-M

Eurnad S.p.A. - A Randomized, Double-Blind, Placebo-Controlled Two-Treatment, Crossover Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) in Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency. EUR-1008-M

Gilead Pharmaceuticals, Inc.- A Phase 3, Double Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients with Pulmonary P. aeruginosa #AIR-CF1. CHMC# 05-03-40

Gilead Pharmaceuticals, Inc.- A Phase 3, Open-Label, Follow-on Study of Multiple Course of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients #AIR-CF3.

Publications, Most Recent

Elder DA, Wooldridge JL, Dolan LM, D’Alessio DA. Glucose Tolerance, Insulin Secretion and Insulin Sensitivity in Children and Adolescents with Cystic Fibrosis and No Prior History of Diabetes.J Pediatr 2007;151(6):653-8.

Prestridge A, Wooldridge JL, Deutsch G, Young LR, MD, Wert SR,Whitsett JA, Nogee L. Persistent Tachypnea and Hypoxia in a 3-month-old Term Infant.J Pediatr 2006;149:702-6.

Wooldridge JL, Deutsch GH, Sontag MK, Osberg I, Chase DR, Silkoff PE, Wagener JS, Accurso FJ. The NO pathway in CF and non-CF children. PediatrPulm 2004;37(4):338-50.

Wooldridge JL, Partrick DA, Bensard DD, Deterding RD. Diaphragmatic Hernia Simulating a Left Pleural Effusion. Pediatr 2003;112:e487-90.

Xu Y, Clark JC, Aranow BJ, Dey CR, Liu C, Wooldridge JL, Whitsett JA. Transcriptional Adaptation to CFTR Deficiency. J Biol Chem 2003;278:7674-82.

Presentations, Most Recent

Visiting Lectureship – Speaker – Riley Hospital for Children , Indianapolis, IN, “Raising the Bar: Quality Improvement in Airway Clearance in the CF Population” July 2005

Professional Organization Memberships

Abstracts

Modi AC, Lim CM, Driscoll KA, Koumoutsos JA, Piazza-Waggoner C, Messer MA, Quittner AL, Wooldridge JL. Intravenous antibiotic treatment of a pulmonary exacerbation: Effects on child and adolescent health related quality of life.Pediatr Pulm 2007;42(S30):A399.

Wooldridge JL, Amaro-Galvez R, Blake K, Chatfield B, McColley S, Woo MS, Straforini C, Anelli M. EUR-1008 is safe and effective in pediatric patients with cystic fibrosis and exocrine pancreatic insufficiency.Pediatr Pulm 2007;42(S30):A522.

Driscoll KA, Piazza-Waggoner C, Modi A, Wooldridge JL, The impact of pediatric pulmonary exacerbation on family functioning and parental anxiety.Pediatr Pulm 2006;41(S29):A540.

Dressman KL,Ernst ML, Wooldridge JL, Fresh start: an innovative approach to improving airway clearance for patients with cystic fibrosis.Pediatr Pulm 2005;40(S27):A408.

Conway E, Blower W, Schultz-Eghtesady K, Prestridge A, Wooldridge JL. Learning how to provide consistent, effective airway clearance to patients with cystic fibrosis.Pediatr Pulm 2005;40(S27):A382.

Elder, DA , Wooldridge, JL , Loudermilk, CW ,Dolan, LM and D'Alessio, DA. Glucose Tolerance in Children and Adolescents with Cystic Fibrosis and No Prior History of Diabetes.American Diabetes Association 2005;1883-P.

Special Interests

Cystic Fibrosis; Cystic Fibrosis related diabetes

Community Activities

Board of Directors- Cystic Fibrosis Foundation, Cincinnati, Ohio (2004-present)
Organizing Committee member of Great Strides – Cystic Fibrosis Foundation fundraising walk, Cincinnati, Ohio (2003, 2004)
Cincinnati’s Finest honoree- Cystic Fibrosis Foundation fundraising event, Cincinnati, Ohio (July 2002-September 2002)